Comprehensive Approaches for HIV Prevention in High-Risk Patients with OUDPremiere Date: Wednesday, December 4, 2019
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 31, 2020
Note: Credit Is No Longer Available
|Jaimie P. Meyer, MD, MS, FACP
Assistant Professor of Medicine
Department of Internal Medicine, Section of Infectious Disease AIDS Program
Yale University School of Medicine
Clinical Assistant Professor
Division of Primary Care/Health Systems in Nursing
Yale School of Nursing
New Haven, CT
|Carlos Malvestutto, MD, MPH
Division of Infectious Diseases
Department of Medicine
Ohio State University Wexner Medical Center
|David Alain Wohl, MD
Professor of Medicine
Institute of Global Health and Infectious Diseases
Site Leader, Global Infectious Diseases Clinical Trials Unit, Chapel Hill Site
The University of North Carolina (UNC) at Chapel Hill School of Medicine
Chapel Hill, NC
There are many consequences of drug abuse, including that, within opioid use disorder (OUD) populations, there is 27 times an increased risk for HIV infection. This has led to a need for education on integrated testing, treatment, and prevention among patients with OUD, particularly on strategies to reduce barriers to pre-exposure prophylaxis (PrEP) initiation in high-risk patients.
The second part of this CME Outfitters Briefcase, a case-based faculty interview, aims to educate clinicians on PrEP for HIV prevention, including what patients are - or are not - candidates for PrEP, as well as the necessary steps to take before initiating PrEP.
At the end of this CE activity, participants should be able to:
- Develop patient-centered strategies for HIV prevention in high-risk OUD populations
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize patient-centered strategies for HIV prevention in high-risk OUD populations.
Supported by an educational grant from Gilead Sciences, Inc.
OUD specialists, primary care physicians, psychiatrists, mental health specialists, physician assistants, nurse practitioners, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.25 contact hours (0.025 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners practicing in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wohl reports that he receives research support from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is a consultant for Gilead Sciences, Inc.
Dr. Malvestutto reports that he is on the advisory committee for ViiV Healthcare.
Dr. Meyer reports that she receives research support from Gilead Sciences, Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kavitha Ramachandran, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).